| 149.23 -6.46 (-4.15%) | 06-05 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 182.37 |
1-year : | 194.47 |
| Resists | First : | 156.14 |
Second : | 166.5 |
| Pivot price | 152.58 |
|||
| Supports | First : | 139.38 |
Second : | 115.97 |
| MAs | MA(5) : | 155.17 |
MA(20) : | 150.99  |
| MA(100) : | 119.04 |
MA(250) : | 79.53 |
|
| MACD | MACD : | 4.8 |
Signal : | 5.9 |
| %K %D | K(14,3) : | 49.5 |
D(3) : | 54.8 |
| RSI | RSI(14): 51.2 |
|||
| 52-week | High : | 166.5 | Low : | 34 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ RVMD ] has closed above bottom band by 32.4%. Bollinger Bands are 37.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 155.07 - 156.04 | 156.04 - 156.72 |
| Low: | 146 - 147.19 | 147.19 - 148.03 |
| Close: | 147.67 - 149.41 | 149.41 - 150.63 |
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Fri, 05 Jun 2026
Why Is Revolution Medicines (RVMD) Up 9.3% Since Last Earnings Report? - Yahoo Finance
Fri, 05 Jun 2026
California Pharma Co. Tests Breakthrough Cancer Drug, Cuts Death Risk 60% - Streetwise Reports
Thu, 04 Jun 2026
Revolution Medicines in the spotlight for earnings post-trial win - Investing.com
Tue, 02 Jun 2026
Revolution Medicines: More Landmark Data Doesn't Dispel Doubts Around Valuation (RVMD) - Seeking Alpha
Tue, 02 Jun 2026
Revolution Medicines' Cancer Drug Trial Shows Promising Results - Intellectia AI
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 213 (M) |
| Shares Float | 194 (M) |
| Held by Insiders | 1.8 (%) |
| Held by Institutions | 95.4 (%) |
| Shares Short | 11,080 (K) |
| Shares Short P.Month | 13,390 (K) |
| EPS | -7.12 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.48 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -37.6 % |
| Return on Equity (ttm) | -76.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -5.32 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -6.5 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -1,060 (M) |
| Levered Free Cash Flow | -606 (M) |
| PE Ratio | -20.99 |
| PEG Ratio | 0 |
| Price to Book value | 19.92 |
| Price to Sales | 0 |
| Price to Cash Flow | -29.94 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|